Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Faguang Jin is active.

Publication


Featured researches published by Faguang Jin.


Lancet Oncology | 2017

Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study

Baohui Han; Kai Li; Q. Wang; Yizhuo Zhao; Li Zhang; Shi Jy; Zhehai Wang; Y. Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li; Yinlan Chen; Jianying Zhou; Donglin Wang

Abstract Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated the efficacy and safety of anlotinib as third-line treatment for advanced non-small-cell lung cancer. Methods We did a randomised, double-blind, placebo-controlled phase 3 trial (ALTER-0303) at 31 sites. Eligible patients with stage 3B/4 non-small-cell lung cancer who progressed after at least two lines of previous therapies were randomly assigned (2:1) to receive anlotinib (12 mg once a day from day 1 to 14 of a 21-day cycle) or placebo until progression or intolerable toxicity. Enrolled patients harbouring EGFR or ALK mutations must have failed in previous match-targeted therapies. The primary endpoint was overall survival. This trial is registered with ClinicalTrials, number NCT02388919. Findings Between February, 2015, and August, 2016, we randomly assigned 437 patients. The baseline characteristics of the anlotinib group (n=294) and placebo group (n=143) were well balanced in age, gender, ECOG performance status, and gene status. With 292 overall survival events (67%), a significant improvement in overall survival was observed in the anlotinib group compared with the placebo group (hazard ratio 0·68, 95% CI 0·54–0·87 p=0·0018), according to investigator-assessed results (table). Interpretation The ALTER-0303 trial met its primary endpoint; anlotinib significantly improved overall survival in advanced non-small-cell lung cancer with a manageable safety profile. The results strongly suggest that anlotinib should be considered as a candidate for the third-line treatment or beyond in advanced non-small-cell lung cancer. Funding Chia-tai Tianqing Pharmaceutical Co Ltd.


Lung Cancer | 2018

Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer

Xiaoyan Si; Li Zhang; Hanping Wang; Xiaotong Zhang; Mengzhao Wang; Baohui Han; Kai Li; Q. Wang; Jianhua Shi; Zhehai Wang; Y. Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li; Yinlan Chen; Jianying Zhou; Donglin Wang

OBJECTIVESnAnlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced non-small-cell lung cancer (NSCLC) patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study assessed quality of life (QoL) in these patients.nnnMETHODSnPatients were randomized (2:1) to anlotinib or placebo up to progression or intolerable toxicity. The QoL were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the associated EORTC Quality of Life Lung Cancer Specific Module (QLQ-LC13) at baseline, end of cycle 1, end of every two cycles, and at the final visit. The analyses were conducted in the first 6 cycles. Differences in scores of 10 points or more between two arms or from baseline were considered clinically meaningful.nnnRESULTSnA total of 437 patients were assigned to anlotinib (nu202f=u202f294) and placebo (nu202f=u202f143). The completion rates of the QoL questionnaires were from 69.9% to 97.0%. Mean scores of QLQ-C30 and QLQ-LC13 subscales were similar in the anlotinib and placebo arms at baseline. Compared to placebo, anlotinib improved role functioning, social functioning, dyspnea, insomnia, constipation and financial problems. Only sore mouth or tongue symptom was worse in the anlotinib arm than in the placebo arm.nnnCONCLUSIONSnAnlotinib improved quality of life versus placebo in advanced NSCLC patients who had received at least two previous chemotherapies. The QoL analyses provided evidence that anlotinib should be a choice for the third-line treatment or beyond in advanced NSCLC.


JAMA Oncology | 2018

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial

Baohui Han; Kai Li; Q. Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Yizhuo Zhao; Hao Yu; Yang Zhao; Weiqiang Chen; Yi Luo; Lin Wu; Xiuwen Wang; Robert Pirker; Kejun Nan; Faguang Jin; Jian Dong; Baolan Li; Sun Y

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug’s efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing after second-line or further treatment. Design, Setting, and Participants The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical trial designed to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC. Patients from 31 grade-A tertiary hospitals in China were enrolled between March 1, 2015, and August 31, 2016. Those aged 18 to 75 years who had histologically or cytologically confirmed NSCLC were eligible (nu2009=u2009606), and those who had centrally located squamous cell carcinoma with cavitary features or brain metastases that were uncontrolled or controlled for less than 2 months were excluded. Patients (nu2009=u2009440) were randomly assigned in a 2-to-1 ratio to receive either 12 mg/d of anlotinib or a matched placebo. All cases were treated with study drugs at least once in accordance with the intention-to-treat principle. Main Outcomes and Measures The primary end point was overall survival. The secondary end points were progression-free survival, objective response rate, disease control rate, quality of life, and safety. Results In total, 439 patients were randomized, 296 to the anlotinib group (106 [36.1%] were female and 188 [64.0%] were male, with a mean [SD] age of 57.9 [9.1] years) and 143 to the placebo group (46 [32.2%] were female and 97 [67.8%] were male, with a mean [SD] age of 56.8 [9.1] years). Overall survival was significantly longer in the anlotinib group (median, 9.6 months; 95% CI, 8.2-10.6) than the placebo group (median, 6.3 months; 95% CI, 5.0-8.1), with a hazard ratio (HR) of 0.68 (95% CI, 0.54-0.87; Pu2009=u2009.002). A substantial increase in progression-free survival was noted in the anlotinib group compared with the placebo group (median, 5.4 months [95% CI, 4.4-5.6] vs 1.4 months [95% CI, 1.1-1.5]; HR, 0.25 [95% CI, 0.19-0.31]; Pu2009<u2009.001). Considerable improvement in objective response rate and disease control rate was observed in the anlotinib group over the placebo group. The most common grade 3 or higher adverse events in the anlotinib arm were hypertension and hyponatremia. Conclusions and Relevance Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. This finding suggests that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC. Trial Registration ClinicalTrials.gov identifier: NCT02388919


Journal of Thoracic Oncology | 2017

P3.03-006 Efficiency of Anlotinib as 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial

B. Han; Kai Li; Q. Wang; Yizuo Zhao; L. Zhang; Jianhua Shi; Zhehai Wang; Y. Cheng; Jiaxi He; S. Yuankai; Wei Chen; Wang X; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li


Journal of Clinical Oncology | 2017

Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC.

Baihui Han; Kai Li; Q. Wang; Yizhuo Zhao; Li Zhang; Jianhua Shi; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li; Yinglan Chen; Jianying Zhou; Donglin Wang


Journal of Clinical Oncology | 2018

Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).

Ying Cheng; Baohui Han; Kai Li; Q. Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li


Journal of Clinical Oncology | 2018

OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR.

Kai Li; Baohui Han; Q. Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li; Jing Wang


Journal of Clinical Oncology | 2018

Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.

Jianhua Shi; Baohui Han; Kai Li; Q. Wang; Li Zhang; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li


Journal of Thoracic Oncology | 2017

P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303

Kai Li; Wang J; B. Han; Y. Zhao; Q. Wang; L. Zhang; Jianhua Shi; Zhehai Wang; Jiaxi He; Yuankai Shi; Y. Cheng; Wei Chen; Wang X; Yi Luo; Kejun Nan; Faguang Jin; J. Dong; Baolan Li; Yinlan Chen; Jian Zhou; Donglin Wang; Xuedong Zhou; Yan Yu; Lijuan Chen; A. Liu; Jiaoti Huang; Cheng Huang; Bangwei Cao; Jun Chen; R. Ma


Journal of Thoracic Oncology | 2017

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Topic: Clinical Trials

Baohui Han; Kai Li; Yizhuo Zhao; Q. Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Jianxing He; Yuankai Shi; Y. Cheng; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Jian Dong; Baolan Li; Jianying Zhou; Yinlan Chen; Donglin Wang; Xin Zhou; Yan Yu; Liming Chen; Anwen Liu; Jianjin Huang; Cheng Huang; Bangwei Cao; Jun Chen; Rui Ma; Zhuang Yu

Collaboration


Dive into the Faguang Jin's collaboration.

Top Co-Authors

Avatar

Baolan Li

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Kai Li

Tianjin Medical University

View shared research outputs
Top Co-Authors

Avatar

Kejun Nan

Xi'an Jiaotong University

View shared research outputs
Top Co-Authors

Avatar

Q. Wang

Zhengzhou University

View shared research outputs
Top Co-Authors

Avatar

Jianxing He

Guangzhou Medical University

View shared research outputs
Top Co-Authors

Avatar

Li Zhang

Peking Union Medical College Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Baohui Han

Shanghai Jiao Tong University

View shared research outputs
Top Co-Authors

Avatar

Yuankai Shi

Academy of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

B. Han

Shanghai Chest Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge